cas 45214-91-3|| where to buy (2S)-5-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid

Nombre del producto:(2S)-5-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid

IUPAC Name:(2S)-2-{[(tert-butoxy)carbonyl]amino}-5-methoxy-5-oxopentanoic acid

Unidad de embalaje	Stock disponible	Precio($)
CM101954-500g	in stock	ŢƄƞ
CM101954-1000g	in stock	źȀȎ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Notas adicionales

Verification code*

refresh

: Núm. De CAS :45214-91-3; Fórmula molecular:C11H19NO6; Punto de fusión:-; Código de sonrisas:O=C(O)[C@@H](NC(OC(C)(C)C)=O)CCC(OC)=O; Densidad:

: Número de catálogo:CM101954; Peso molecular:261.27; Punto de ebullición:428.4°C at 760 mmHg; Nº Mdl:MFCD00190794; Almacenamiento:Store at room temperature.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Bomedemstat; Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.